PRM Perimeter Group Inc.
Chemicals & Allied Products · NYSE · SEC CIK 1880319 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY30.7%
TTM net income YoY-28.8%
TTM EPS YoY-59.3%
Revenue 3-yr CAGR39.9%
Net income 3-yr CAGR4.4%
Margins
Gross margin54.5%
Operating margin14.5%
Net margin6.7%
FCF margin6.5%
EBITDA margin27.3%
Returns
ROE4.6%
ROA1.8%
ROIC (approx.)6.3%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets60.8%
Debt / equity0.91x
Current ratio2.79x
Interest coverage1.63x
Cash quality & payout
Operating cash flow / net income1.66x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue4.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $652.86M | $560.97M |
| Cost of revenue | $277.71M | $243.88M |
| Gross profit | $375.15M | $317.09M |
| SG&A expense | $77.58M | $66.90M |
| Operating income | -$200.93M | -$3.77M |
| Interest expense | $39.13M | $40.46M |
| Pretax income | -$236.25M | -$46.86M |
| Income tax | -$29.88M | -$40.96M |
| Net income | -$206.37M | -$5.91M |
| EBITDA | -$126.90M | $61.95M |
| EPS (basic) | -1.37 | -0.04 |
| EPS (diluted) | -1.37 | -0.04 |
| Weighted avg. shares (diluted) | 150.37M | 145.71M |
| Balance sheet | ||
| Cash & equivalents | $325.93M | $198.46M |
| Short-term investments | — | $0 |
| Receivables | $64.36M | $56.05M |
| Inventory | $139.63M | $116.35M |
| Current assets | $563.97M | $394.02M |
| PP&E, net | $85.14M | $64.78M |
| Goodwill | $1.07B | $1.03B |
| Intangibles | $899.32M | $898.42M |
| Total assets | $2.65B | $2.42B |
| Current liabilities | $175.12M | $62.49M |
| Long-term debt | $669.12M | $667.77M |
| Total debt | $669.12M | $667.77M |
| Total liabilities | $1.52B | $1.26B |
| Shareholders' equity | $1.13B | $1.16B |
| Net debt | $343.19M | $469.32M |
| Shares outstanding | 149.44M | 147.82M |
| Cash flow statement | ||
| Operating cash flow | $238.15M | $188.39M |
| Capital expenditure | $29.59M | $15.53M |
| Free cash flow | $208.56M | $172.86M |
| Investing cash flow | -$106.82M | -$42.94M |
| Financing cash flow | -$8.97M | $8.35M |
| Depreciation & amortization | $74.03M | $65.72M |
| Stock-based compensation | $16.65M | $12.85M |
| Share buybacks | $40.37M | $14.42M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.